Bernasconi R, Klein M, Martin P, Christen P, Hafner T, Portet C, Schmutz M
Biology Research Laboratories, Pharmaceuticals Division, Ciba-Geigy Ltd, Basle, Switzerland.
J Neural Transm. 1988;72(3):213-33. doi: 10.1007/BF01243421.
Biochemical and pharmacological effects of gamma-vinyl GABA (Vigabatrin, GVG), and irreversible enzyme-activated inhibitor of 4-aminobutyrate: 2-oxoglutarate aminotransferase (EC 2.6.1.19; GABA-T), were measured in mice. This anticonvulsant produced a time- and dose-dependent elevation of the GABA, phenylalanine and lysine contents of cortical tissue and simultaneously decreased glutamate, aspartate and alanine levels. In addition, GVG caused a biphasic change in glutamine concentrations (a decline 1-4 hours after administration, followed 20 hours later by an increase). Moreover, we found a new, as yet unidentified amino acid in the brain eluting with the same retention time as alpha-aminoadipic acid from an HPLC cation-exchange column. The level of this novel chemical entity was greatly increased by GVG 20 hours after injection of the drug. At all tested intervals between 1 and 60 hours after injection, GVG was ineffective against maximal electroshock. The GABA-T inhibitor dose-dependently protected mice against isoniazid-induced seizures, simultaneously causing an increase in brain GABA concentrations. However, this apparent correlation applied only until 4 hours after treatment. To better define the anticonvulsant profile of GVG, groups of mice were treated, 1, 2, 4, and 24 hours prior to challenge with convulsant doses of strychnine, pentetrazole (PTZ), and picrotoxin, and brain amino acid levels, including brain concentrations of GVG, were measured. In all instances, the time dependency of the anticonvulsant effects of GVG and of increases in brain GABA levels differed. Amino acid concentrations in animals treated only with GVG were similar to those in animals given GVG and a chemical convulsant. GVG showed no selectivity for seizures produced by impairment of GABA-ergic neurotransmission. Although GVG is an effective GABA-T inhibitor, it apparently affects several other pyridoxal-phosphate-dependent cerebral enzymes and/or interacts with other neurotransmitter systems as well.
在小鼠中测定了γ-乙烯基γ-氨基丁酸(vigabatrin,GVG)的生化和药理作用,它是4-氨基丁酸:2-氧代戊二酸转氨酶(EC 2.6.1.19;GABA-T)的不可逆酶激活抑制剂。这种抗惊厥药使皮质组织中的GABA、苯丙氨酸和赖氨酸含量呈时间和剂量依赖性升高,同时降低了谷氨酸、天冬氨酸和丙氨酸水平。此外,GVG导致谷氨酰胺浓度出现双相变化(给药后1 - 4小时下降,20小时后升高)。此外,我们在大脑中发现了一种新的、尚未鉴定的氨基酸,它从高效液相色谱阳离子交换柱上洗脱时的保留时间与α-氨基己二酸相同。注射药物20小时后,这种新化学物质的水平因GVG而大幅升高。在注射后1至60小时的所有测试时间间隔内,GVG对最大电休克均无效。GABA-T抑制剂能剂量依赖性地保护小鼠免受异烟肼诱导的惊厥,同时使脑内GABA浓度升高。然而,这种明显的相关性仅在治疗后4小时内成立。为了更好地界定GVG的抗惊厥特征,在给予惊厥剂量的士的宁、戊四氮(PTZ)和印防己毒素之前1、2、4和24小时对几组小鼠进行治疗,并测量脑氨基酸水平,包括脑内GVG的浓度。在所有情况下,GVG的抗惊厥作用和脑内GABA水平升高的时间依赖性均不同。仅用GVG治疗的动物中的氨基酸浓度与给予GVG和化学惊厥剂的动物中的相似。GVG对由GABA能神经传递受损引起的惊厥没有选择性。尽管GVG是一种有效的GABA-T抑制剂,但它显然还会影响其他几种依赖磷酸吡哆醛的脑酶和/或与其他神经递质系统相互作用。